TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35204752

Group type: EXPERIMENTAL
Intervention: Cy5-CCN2(IV) administered via intraperitoneal and direct intra-renal injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cy5-CCN2(IV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGFR gene silencing in cultured tubular epithelial cells
Number of subjects: 0
Study: 35205346

Group type: EXPERIMENTAL
Intervention: Copper tolerance treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 35205614

Group type: EXPERIMENTAL
Intervention: Human circulating progastrin (hPG)
Number of subjects: 0
Study: 35205765

Group type: EXPERIMENTAL
Intervention: R-CHOP14 regimen
Number of subjects: 0
Study: 35206335

Group type: EXPERIMENTAL
Intervention: Job control (79.2 ± 14.9)
Number of subjects: 9257

Group type: EXPERIMENTAL
Intervention: Job support (25.2 ± 5.1)
Number of subjects: 9257

Group type: COMPARATOR
Intervention: Risk of job strain and isostrain
Number of subjects: 9257
Study: 35206392

Group type: EXPERIMENTAL
Intervention: Characteristics of the ECEC environment (outdoor and indoor play environment quality, outdoor and indoor play equipment, screen-time environment quality, policy environment quality)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progressive Aerobic Cardiovascular Endurance Run (PACER)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children's Activity and Movement in Preschool Study (CHAMPS) motor skills protocol (CMSP)
Number of subjects: 0
Study: 35208884

Group type: EXPERIMENTAL
Intervention: Nine-strain synbiotic
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-colicky babies (control group)
Number of subjects: 100
Study: 35209871

Group type: EXPERIMENTAL
Intervention: AM80 with gemcitabine (GEM) and nab-paclitaxel (nab-PTX)
Number of subjects: 0
Study: 35209952

Group type: EXPERIMENTAL
Intervention: Trx80 levels in the GEDOC cohort
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Trx80 levels in the FINGER cohort
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Trx80 levels in both cohorts
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Trx80 levels in AD patients with ApoE4 genotype
Number of subjects: 146
Study: 35210075

Group type: EXPERIMENTAL
Intervention: HIGH AF (≥24 hours)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: MID AF (6 minutes to 24 hours)
Number of subjects: 869

Group type: COMPARATOR
Intervention: NO AF (<6 minutes)
Number of subjects: 869
Study: 35210077

Group type: EXPERIMENTAL
Intervention: Conformal Left Atrial Appendage Seal, Conformal Medical Inc
Number of subjects: 15
Study: 35210262

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 893

Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 893
Study: 35210307

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for up to four doses, followed by nivolumab 480 mg every 4 weeks for ≤2 years)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 52
Study: 35210326

Group type: EXPERIMENTAL
Intervention: T2-high asthma phenotype
Number of subjects: 1125
Study: 35210531

Group type: EXPERIMENTAL
Intervention: Intravenous 0.9 mg/kg alteplase within 4.5 h (ACS group)
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Intravenous 0.9 mg/kg alteplase within 4.5 h (PCS group)
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Intravenous 0.9 mg/kg alteplase within 4.5 h (ACS and PCS groups)
Number of subjects: 1194
Study: 35210595

Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 7215

Group type: COMPARATOR
Intervention: Control
Number of subjects: 7215
Study: 35210606

Group type: EXPERIMENTAL
Intervention: mRNA-HB27-LNP; administered intravenously; single prophylactic administration.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mRNA-HB27-LNP; administered prophylactically in a close contact transmission model.
Number of subjects: 0
Study: 35210758

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 3719
Study: 35210852

Group type: EXPERIMENTAL
Intervention: Sequential melphalan-based conditioning therapy
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Blast count >20% prior to conditioning
Number of subjects: 173
Study: 35211079

Group type: EXPERIMENTAL
Intervention: Natural history data from 41 patients with longitudinal assessments in the DEM-CHILD DB (NCT04613089)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Natural history data
Number of subjects: 140

Group type: COMPARATOR
Intervention: Natural history data accepted by EMA and FDA
Number of subjects: 140
Study: 35211080

Group type: EXPERIMENTAL
Intervention: MyoPro™ orthosis used in motor learning-based therapy
Number of subjects: 13
Study: 35211494

Group type: EXPERIMENTAL
Intervention: Malnutrition group (n=1258, 60.4% of patients)
Number of subjects: 2083

Group type: COMPARATOR
Intervention: Non-malnutrition group (n=825, 39.6% of patients)
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Malnutrition group (age ≤ 75 years)
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Malnourished patients with CA-AKI
Number of subjects: 2083
Study: 35211517

Group type: EXPERIMENTAL
Intervention: AF catheter ablation (AFCA)
Number of subjects: 1353
Study: 35211772

Group type: EXPERIMENTAL
Intervention: Hospital Time ≤ 6 hours
Number of subjects: 2749

Group type: EXPERIMENTAL
Intervention: Hospital Time 6-12 hours
Number of subjects: 2749

Group type: EXPERIMENTAL
Intervention: Hospital Time 12-18 hours
Number of subjects: 2749

Group type: EXPERIMENTAL
Intervention: Hospital Time 18-24 hours
Number of subjects: 2749

Group type: COMPARATOR
Intervention: Patients with symptom onset > 24 hours
Number of subjects: 2749
Study: 35211773

Group type: EXPERIMENTAL
Intervention: Clinical decision aid for midfacial trauma (facial depression, epistaxis, ocular movement limitation, palpable step-off, objective malocclusion, tooth mobility or avulsion)
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Clinical decision aid for mandibular trauma (mouth opening limitation, jaw movement pain, objective malocclusion, tooth mobility or avulsion)
Number of subjects: 766
Study: 35211793

Group type: EXPERIMENTAL
Intervention: eGFR CKiD (bedside Schwartz equation)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: eGFR EKFC
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: modified CKD-EPI40
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: eGFR CKiD under 25 (CKiDU25)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: eGFR FAS age
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: eGFR FAS height
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: adjusted-creatinine revised Lund-Malmö (LMR18)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Serum creatinine (SCr)
Number of subjects: 600
Study: 35211796

Group type: EXPERIMENTAL
Intervention: Urinary [TIMP-2]*[IGFBP7] measured using NEPHROCHECK® at eight perioperative time points
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Urinary [TIMP-2]*[IGFBP7]
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: NEPHROCHECK® test added to postoperative parameters
Number of subjects: 230
Study: 35211837

Group type: EXPERIMENTAL
Intervention: Ultrasound Perfusion Imaging (UPI)
Number of subjects: 30
Study: 35211851

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding until 6 months
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Never breastfed exclusively
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Early introduction of solid foods
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Weaning after the 4th month of age
Number of subjects: 45
Study: 35211872

Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF) in GA/DRF group
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF) in IFN/DRF group
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF) in DRF-rollover group
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF) in DMF-rollover group
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF) overall
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF) after 2 years
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF) after transition from GA or IFN
Number of subjects: 1057
Study: 35212017

Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive interventions (JITAIs) during cognitive-behavioral therapy (CBT-E)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT-E) without JITAIs
Number of subjects: 55
Study: 35212262

Group type: EXPERIMENTAL
Intervention: Bilateral masseter EMG (2M)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bilateral temporalis EMG (2T)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Unilateral masseter EMG (1M)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Unilateral temporalis EMG (1T)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Unilateral chin EMG (1C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bilateral chin EMG (2C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Reference standard (4MT)
Number of subjects: 10
Study: 35212260

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Number of subjects: 69001
Study: 35212470

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART)
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: Drug use
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: No drug use and no experience of violence with ART
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: Experience of violence
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: Moderate internalized stigma
Number of subjects: 1363

Group type: COMPARATOR
Intervention: Drug use and experience of violence
Number of subjects: 1363
Study: 35212486

Group type: EXPERIMENTAL
Intervention: GLA gene variant c.376A>G (p.Ser126Gly)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Follow-up examination after 12 years
Number of subjects: 5
Study: 35212633

Group type: EXPERIMENTAL
Intervention: BRAVE intervention delivered via SMS text messaging, including role model videos, mental wellness strategies, and social support, with 3 to 5 messages per week.
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: BRAVE intervention content (including role model videos)
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: BRAVE intervention
Number of subjects: 1030
Study: 35212640

Group type: EXPERIMENTAL
Intervention: Vaccine-promoting intervention for vaccine hesitancy reduction
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 120
Study: 35212639

Group type: EXPERIMENTAL
Intervention: GNN + OPS
Number of subjects: 300

Group type: COMPARATOR
Intervention: GNN + COVID-19 ORR
Number of subjects: 300
Study: 35212779

Group type: EXPERIMENTAL
Intervention: Crenolanib (oral, once daily)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Crenolanib with acid reducer cotreatment
Number of subjects: 55
Study: 35212906

Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole (RIB + LET)
Number of subjects: 39
Study: 35213039

Group type: EXPERIMENTAL
Intervention: Abbreviated endocrine therapy duration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended endocrine therapy
Number of subjects: 0
Study: 35213495

Group type: EXPERIMENTAL
Intervention: StdPPM without fixation
Number of subjects: 25190

Group type: EXPERIMENTAL
Intervention: StdPPM with metal tacks
Number of subjects: 25190

Group type: EXPERIMENTAL
Intervention: StdPPM with fibrin glue
Number of subjects: 25190

Group type: EXPERIMENTAL
Intervention: LWM with fibrin glue
Number of subjects: 25190

Group type: EXPERIMENTAL
Intervention: LWM with metal tacks
Number of subjects: 25190

Group type: EXPERIMENTAL
Intervention: LWM with absorbable tacks
Number of subjects: 25190

Group type: EXPERIMENTAL
Intervention: LWM without fixation
Number of subjects: 25190
Study: 35213523

Group type: EXPERIMENTAL
Intervention: Wireless single-lead ECG monitoring
Number of subjects: 398

Group type: COMPARATOR
Intervention: Peripheral oxygen saturation (Spo2) <85% for >5 minutes
Number of subjects: 398
Study: 35213528

Group type: EXPERIMENTAL
Intervention: Subretinal drusenoid deposits (SDD)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Non-SDD (drusen only)
Number of subjects: 126
Study: 35213713

Group type: EXPERIMENTAL
Intervention: Obesity clinic group (overweight/obesity)
Number of subjects: 2154

Group type: COMPARATOR
Intervention: Population-based group (normal weight)
Number of subjects: 2154
Study: 35213728

Group type: EXPERIMENTAL
Intervention: Eumenorrheic women
Number of subjects: 38

Group type: COMPARATOR
Intervention: Oral contraceptive users
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: All data pooled
Number of subjects: 38
Study: 35213769

Group type: EXPERIMENTAL
Intervention: Patisiran
Number of subjects: 23
Study: 35214767

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 0
Study: 35216589

Group type: EXPERIMENTAL
Intervention: Principal Component Regression (PCR) models
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Bayesian Kernel Machine Regression (BKMR) models
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Both approaches (PCR and BKMR)
Number of subjects: 388
Study: 35216638

Group type: EXPERIMENTAL
Intervention: Home-based moderate-to-vigorous intensity exercise intervention (one aerobic exercise session at 80-90% VO2 max)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 35216832

Group type: EXPERIMENTAL
Intervention: Hysteroscopic myomectomy
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Abdominal myomectomy
Number of subjects: 1095
Study: 35216968

Group type: EXPERIMENTAL
Intervention: Risk-reducing salpingo-oophorectomy
Number of subjects: 218

Group type: COMPARATOR
Intervention: Ovarian cancer screening (Control)
Number of subjects: 218
Study: 35217573

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study: 35217576

Group type: EXPERIMENTAL
Intervention: Blood-based tumor mutational burden (bTMB) using a TMB panel of 1.1 Mb
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Blood-based tumor mutational burden (bTMB)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Blood-based tumor mutational burden (bTMB) in stage IV samples with at least 20 ng of cfDNA input
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Minimized bTMB panel to a subset of 577 kb
Number of subjects: 185
Study: 35218024

Group type: EXPERIMENTAL
Intervention: Neural network predicted rectal dose for patients with rectal spacer insertion
Number of subjects: 44
Study: 35218324

Group type: EXPERIMENTAL
Intervention: Ligelizumab 72 mg
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Ligelizumab 240 mg
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study: 35218366

Group type: EXPERIMENTAL
Intervention: COVID patients
Number of subjects: 2086

Group type: COMPARATOR
Intervention: Non-COVID patients
Number of subjects: 2086
Study: 35218665

Group type: EXPERIMENTAL
Intervention: Chronic Sleep Restriction (CSR)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Recovery Sleep
Number of subjects: 9
Study: 35219065

Group type: EXPERIMENTAL
Intervention: ONC206
Number of subjects: 0
Study: 35219300

Group type: EXPERIMENTAL
Intervention: Preoperative chemo-radiotherapy (pre-CRT)
Number of subjects: 222
Study: 35219315

Group type: EXPERIMENTAL
Intervention: Boys (stunting prevalence)
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: Girls (stunting prevalence)
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: Boys (wasting prevalence)
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: Girls (wasting prevalence)
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: Untimely initiation of breastfeeding (Boys)
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: Untimely initiation of breastfeeding (Girls)
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: Untimely introduction to complementary food
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: Low consumption of legumes/nuts
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: Low egg consumption (Girls)
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: Region of residence and age of the mother
Number of subjects: 2036
Study: 35219622

Group type: EXPERIMENTAL
Intervention: NiTiDES stent (Alvimedica)
Number of subjects: 100
Study: 35219724

Group type: EXPERIMENTAL
Intervention: Rectal LNPCPs
Number of subjects: 3405
Study: 35220448

Group type: EXPERIMENTAL
Intervention: TMAO
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: TMAO, choline, and carnitine above the median
Number of subjects: 1726
Study: 35220460

Group type: EXPERIMENTAL
Intervention: Preoperative anaemia
Number of subjects: 9081
Study: 35220658

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir
Number of subjects: 384
Study: 35220665

Group type: EXPERIMENTAL
Intervention: Socioeconomic constraints (measured by Federal Poverty Level, receipt of public assistance, difficulty paying for housing, food, and other necessities)
Number of subjects: 2581

Group type: EXPERIMENTAL
Intervention: Sexual wellbeing measures (sexual functioning and satisfaction, frequency of orgasm, current sex-life rating)
Number of subjects: 2581
Study: 35220688

Group type: EXPERIMENTAL
Intervention: TMD patients (n=47)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Healthy participants (age- and sex-matched control group, n=47)
Number of subjects: 94
Study: 35221224

Group type: EXPERIMENTAL
Intervention: Whole-body insulin clearance
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Glomerular filtration rate (GFR)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Effective renal plasma flow (ERPF)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity (M value)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Lean body mass
Number of subjects: 44
Study: 35221650

Group type: COMPARATOR
Intervention: Serratus plane block (SPB) alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of pectoral type 1 (PECS I) and serratus plane block (SPB)
Number of subjects: 60
Study: 35221687

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study: 35221928

Group type: EXPERIMENTAL
Intervention: Heterotopic Ossification treatment, specific details not available
Number of subjects: 0
Study: 35222036

Group type: EXPERIMENTAL
Intervention: SHR2285, a small-molecule Factor XIa inhibitor
Number of subjects: 0
Study: 35222057

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Patient phenotyping in HFpEF
Number of subjects: 180
Study: 35222077

Group type: EXPERIMENTAL
Intervention: Visceral adiposity (measured via MRI)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers (IL-6, TNF-α, CRP)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Testosterone levels
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Citrate synthase (CS) activity
Number of subjects: 33
Study: 35222195

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Mindful self-compassion meditation
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Self-induced cognitive trance (SICT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 160
Study: 35222248

Group type: EXPERIMENTAL
Intervention: EVT after IV alteplase (combination-therapy group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EVT alone (EVT-alone group)
Number of subjects: 0
Study: 35222429

Group type: EXPERIMENTAL
Intervention: COVID-19 cases
Number of subjects: 516

Group type: COMPARATOR
Intervention: Non-COVID-19 controls
Number of subjects: 516
Study: 35222719

Group type: EXPERIMENTAL
Intervention: Alprostadil treatment (Group A, n=52)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Alprostadil plus hyperbaric oxygen (HBO) treatment (Group B, n=52)
Number of subjects: 104
Study: 35222735

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction training (MBSR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FibroQoL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35223458

Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 mg every 12 hours in combination with letrozole (Part A, n=20)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 mg every 12 hours in combination with anastrozole (Part B, n=16)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 mg every 12 hours in combination with tamoxifen (Part C, n=16)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 mg every 12 hours in combination with exemestane (Part D, n=15)
Number of subjects: 67
Study: 35223882

Group type: EXPERIMENTAL
Intervention: Initial photodynamic therapy (PDT) with intravitreal injection of conbercept (IVC)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Delayed photodynamic therapy (PDT) with intravitreal injection of conbercept (IVC)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Initial PDT with IVC
Number of subjects: 86

Group type: COMPARATOR
Intervention: Delayed PDT with IVC
Number of subjects: 86
Study: 35224534

Group type: EXPERIMENTAL
Intervention: Combination of linguistic and acoustic features in semi-structured conversations
Number of subjects: 0
Study: 35224712

Group type: EXPERIMENTAL
Intervention: Any admission in the preceding 2 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hematocrit at ED arrival ≤ 35%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-existing cardiovascular disease (valvular disease or myocardial infarction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NIMV at discharge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No appointment with a specialist after discharge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-reported need for help at home
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EuroQol EQ-5D score before the admission
Number of subjects: 0